White HouseUS Pharma PricesNine Big Pharma to cut US drug prices in Most-favoured Nations dealsNine pharma giants will cut US drug prices up to 90 % via TrumpRx and direct channels, following previous Pfizer and AstraZeneca MFN deals. more ➔
ClarivateUS Biosecure ActTrump Administration tables new version of Biosecure ActThe Trump administration has tabled a new Biosecure Act, prompting industry concern over oversight shift, regulatory uncertainty and need for stronger US biotech strategy. more ➔
H. Zell - wikipedia.orgagri-biotechEU committee approves New Plant Breeding (NGT) techniquesOn Friday, the EU committee of Permanent Representatives of EU Member States backed the deregulation of new genomic plant breeding techniques, easing regulation for NGT1 crops. more ➔
FDARegulatoryEgetis Therapeutics AB submits rolling NDA for tiratricolEgetis Therapeutics has submitted a rolling NDA for Tiratricol to treat rare MCT8 transporter deficiency. The application for priority review is based on positive ReTRIACt study results. more ➔
University of GenevaFinancingFoRx raises US$50m in Series A to advance PARG inhibitorSwiss cancer specialist FoRx Therapeutics AG has secured US$50m Series A to fund Phase I development of FORX-428, supporting IND, trial execution and clinical data readout by mid-2026. more ➔
MRM Health NVAntiinflammationBelgian microbiome player MRM Health initiates R&D partnership in cancer immunotherapyFollowing a €55m (US$64m) Series B financing in September, Ghent-based MRM Health today announced a strategic collaboration with the research group of Professor Emile Voest, Senior Group Leader at … more ➔
EC- press serviceEUBiopharmaceutical sector welcomes EU Biotech ActThe European Commission has unveiled the first part of its draft for a Biotech Act, focusing on health and medical biotechnology. The proposal has won strong support from industry stakeholders, who … more ➔
John Kiel - wikipediaM&ASobi strengthens gout pipeline with Arthrosi acquisitionSobi AB has completed the US$1.5bn acquisition of Chinese Arthrosi Therapeutics Ltd. Its lead candidate, pozdeutinurad, a URAT1 inhibitor for gout, is in pivotal global Phase-III trials, with China licensing … more ➔
Sanofimultiple sclerosisSanofi facing tolebrutinib setback in MSSanofi’s tolebrutinib fails Phase III in PPMS, while FDA postpones decision on targeted therapy approval for nrSPMS. more ➔
FIDA Biosystems ApSFinancingEifo and Fsg back Fida Biosystems with €5m investmentFida Biosystems ApS has added €5m from EIFO and FSG to an ongoing Series A financing to scale its Flow-Induced Dispersion Analysis platform, advancing in-solution biophysical analysis for drug d … more ➔
White House
Clarivate
H. Zell - wikipedia.org
FDA
University of Geneva
MRM Health NV
EC- press service
John Kiel - wikipedia
Sanofi
FIDA Biosystems ApS